Kips Biopharma Unveils New CI Following Name Change, Emphasizing 'Sustainable Biotech'

Kips BioPharma (formerly KPS), which completed its transformation into a pharmaceutical company through a name change, unveiled its new corporate identity (CI) on the 1st.

According to the company, the new CI was designed to harmonize with the meaning of its mission as a "sustainable biotech company." The symbol logo, the initial K, was inspired by chromosomes. The vibrant tones of blue and green colors symbolize the vision of an innovative, growing, and progressive biotech company.

Earlier, on the 28th of last month, the company held a shareholders' meeting and passed the amendment to change its name from KPS to Kips BioPharma. Additionally, KB BioMed, an oral drug delivery platform developer acquired last month, also completed its name change to "Kips BioMed" to enhance identity with the parent company.

Kips BioPharma aims to focus on developing its core pipelines this year, the first year of its new start, to achieve visible results. For the first pipeline, the anticancer drug candidate Idetrexed, the first patient recruitment for the PARP inhibitor (PARPi) combination Phase 1b clinical trial led by the UK Institute of Cancer Research (ICR) is scheduled for this month.

The second pipeline, the "oral drug" platform, plans to enter nonclinical studies on primates this month to verify the bioavailability of oral insulin and oral glucagon-like peptide-1 (GLP-1). If a double-digit high bioavailability is confirmed, as seen in rodent experiments conducted independently, it is expected to have a significant market impact.

Kim Ha-yong, CEO of Kips BioPharma, stated, "The five-year preparation period of strengthening the company's scale and substance through mergers and acquisitions?from acquiring a listed company to transforming into a pharmaceutical company?has ended, and now we expect substantial results in our core bio business." He added, "This year, we will present our vision with tangible outcomes such as technology export contracts with global big pharma."